(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- Obamacare enrollment declines as US subsidies expire
- Ukraine proved this drone-killer works. Now, the West is giving it a shot.
- Are your hormones imbalanced? Doctors explain how to know if you need testing
- From Representative to Business visionary: Private issue Victories
- From Amateur to Master: My Involvement in Photography
- Instructions to Pick the Best Album Rates for Your Investment funds
- Students were skipping my astrophysics class to play video games – so I turned the class itself into a video game
